Abstract:ID 93958 Poster Board 481 A 3 adenosine receptor (AR) agonists are being developed for the treatment of autoimmune inflammatory diseases, chronic pain and cancer. A 3 AR agonists are not limited by cardiovascular side effects observed with other adenosine (A 1 and A 2A ) agonists that were in clinical trials. 2-Arylethynyl (North)-methanocarba adenosines have been explored as highly selective A 3 AR agonists, which is largely a function of the pseudoribose (bicyclic fused cyclopropane and cyclopentane) ring that pre-establishes a preferred (N) conformation for receptor recognition. Here, we compare analogues in the 5¢methylamide series having bulky C2-substitution, which either contain or lack an ethynyl spacer between adenine and a cyclic group. 2-Aryl compounds 11 , 13 , 14 , 19 , 22 , 23 , 27 , 29 , 31 and 34 , lacking an ethynyl spacer, displayed potent K i values of 2–30 nM at the human (h) A 3 AR, while other derivatives had greatly reduced affinity. The mouse (m) A 3 AR affinity was highly variable, with 2-arylethynyl groups greatly favoring high affinity ( 7 , 8 > 3c , 3d > 3b ) compared to 2-aryl analogues. However, 4¢truncated derivatives lacking a 2-ethynyl spacer had greatly reduced hA 3 AR affinity, even for those analogues containing affinity-enhancing N 6 -dopamine-derived substituents. This suggests that the 5¢methylamide group is especially important for anchoring these analogues in a deep hydrophilic subpocket in the receptor. hA 3 AR homology modeling indicated that 2-aryl and 2-arylethynyl groups have different conformations and receptor environments. The directly connected 2-aryl groups interact with ECL2 of the hA 3 AR, as opposed to the 2-arylethynyl groups, which interact with TM2. Functional assays of selected compounds in G protein-dependent and independent signaling were performed using engineered HEK293T cell lines. In a hA 3 AR miniG α i recruitment assay, 31 (MRS8062) was (slightly) more potent compared to a β-arrestin2 recruitment assay, and its maximal efficacy (E max ) was much higher (165%) than reference nonselective agonist NECA. Thus, in the 2-aryl series, A 3 AR affinity and selectivity were variable and generally reduced compared to the 2-arylethynyl series, with a greater dependence on the specific aryl group present. Selected compounds were protective in an vivo ischemic model of peripheral artery disease (PAD), in which other A 3 AR agonists demonstrated efficacy. Compounds 3a – 3c in the rigidified 2-arylethynyl series significantly decreased the % cell death in this model of skeletal muscle ischemia reperfusion injury/claudication, as previously shown only for moderately A 3 AR-selective ribosides or (N)-methanocarba derivatives (all lacking the 2-arylethynyl group). Thus, we have expanded A 3 AR agonist SAR for (N)-methanocarba adenosines and their application to skeletal muscle ischemia. NIDDK Intramural Res. ZIADK031117

Comparison of the Selectivity of Human Adenosine Receptor Antagonists Based on Structure and Pharmacophore Features

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A 3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary

Integrating Pharmacophore Into Membrane Molecular Dynamics Simulations To Improve Homology Modeling Of G Protein-Coupled Receptors With Ligand Selectivity: A(2a) Adenosine Receptor As An Example

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Progress in the pursuit of therapeutic adenosine receptor antagonists

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

Species dependence of A3 adenosine receptor pharmacology and function

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Medicinal chemistry of adenosine A3 receptor ligands

Concentration-Dependent bidirectional regulation of adenosine receptor A1 explored through machine learning

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

Structural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Cryo-EM structures of adenosine receptor A3AR bound to selective agonists

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists